论文部分内容阅读
目的在肝硬化及肝癌患者中应用垂体后叶素,了解其致肝细胞凋亡,肝纤维化情况。方法垂体后叶素12U治疗21例肝硬化及肝癌患者,监测治疗前,用药30min时及用药结束时的谷丙转氨酶。以高于谷丙转氨酶正常值上限2倍以上为较严重肝损害。结果21例患者用药30min时及用药结束时,谷丙转氨酶升高均无超过未用药前的两倍以上者。结论垂体后叶素用药近期无较严重致肝细胞凋亡、肝纤维化的作用。垂体后叶素致肝细胞凋亡及肝纤维化的作用,仍待深入研究。
Objective To apply pituitrin in patients with cirrhosis and hepatocellular carcinoma to understand the hepatocyte apoptosis and hepatic fibrosis. Methods Pituitrin 12U was used to treat 21 patients with cirrhosis and hepatocellular carcinoma, and the alanine aminotransferase (ALT) was monitored before treatment, 30 minutes after treatment and at the end of treatment. Higher than the normal limit of alanine aminotransferase more than 2 times the more serious liver damage. Results 21 patients with medication 30min and the end of medication, alanine aminotransferase did not rise more than twice before without medication. Conclusion There was no severe severe hepatocellular apoptosis and hepatic fibrosis in vasopressin treatment. Pituitrin induced hepatocyte apoptosis and liver fibrosis, remains to be further studied.